Javitt Keynote Speaker and Biotech Conference
I'm signed up for the Sachs 20th Annual European Biotech conference scheduled for next week in which Dr. Javitt will be one of the keynote speakers. On Monday, Sept 21st, Dr. Javitt will speak at 16:00 (CET). Looks like he is speaking for about 20 minutes. After his speech, there will be a panel discussion titled "Therapeutic Strategies to Prevent & Treat Covid-19" with the following participants:
Max Herrmann, Managing Directior, Stifel Financial Corp
Rao MOvva, Novartis Distinguished Scientist & Independent Pharma & Biotech advisor
Dave Hallett, COO, Exscientia Ltd
Edward Littler, Founder, Collaborative Community against Coronavirus (3C)
Gilead Raday, COO, RedHill Biopharma Ltd.
Richard Marsden, CEO, Synairgen Plc
Also, I found Dr. Javitt's bio listed on the conference website to be interesting. Please read below:
"Jonathan Javitt
Chairman & CEO, NeuroRx, Inc.
Jonathan is a physician, health economist, and health policy expert, who has a 30 year history of combining clinical understanding with expertise in medical device and drug development, health information technology, health policy, and health economics.
Currently, he serves as CEO of NeuroRx, Inc., which is developing SamiVir™ (aviptadil) to treat Respiratory Failure in Critical COVID-19 and to prevent respiratory failure in moderate COVID-19. SamiVir blocks coronavirus replication, cytokine production, and cell death in human lung cells. NeuroRx is also developing NRX-101, an FDA-designated Breakthrough drug targeting suicidal depression and PTSD. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and the Wilmer Ophthalmological Institute, of Johns Hopkins University, where he remains a member of the faculty.
He has served on drug and device development teams for Merck, Pharmacia, Pfizer, Bayer, Allergan, Alcon, and Eyetech, where he helped to pioneer the integration of pharmacoeconomic outcomes and patient quality of life into the drug and device clinical trials and product approvals. His experience includes regulatory expertise in FDA and CE compliance with the drug and device approval process and quality system management.
Jonathan has been a founder of 6 health informatics and analytics companies that have gone on to successful public acquisitions: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX) and Coderyte, Inc., (NYSE:3M), and Telcare, Inc., funded by Qualcomm Ventures, Sequoia Capital, and Norwest Venture Partners.
Prof. Javitt has served as a senior health advisor to three US Presidential administrations. Most recently, he was commissioned by President Bush to chair the Health Subcommittee of the President’s Information Technology Advisory Committee (PITAC) which created the blueprint for the Office of the National Coordiator for Health IT and the HITECH act. He also served as a Special Employee of the Undersecretary of Defense. He is a Senior Fellow in the National Security Health Policy Center of the Potomac Institute for Policy Studies since September 2001. He has been also served as a consultant to the World Bank, the National Institutes of Health, the Health Care Financing Administration, Department of Veterans Affairs, and the ministries of health of United Kingdom, Sweden, Australia, Japan, Israel, and the Netherlands.
Jonathan graduated from the Harvard T.H. Chan School of Public Health in 1982 and has been granted its 2015 Alumnus of Merit award. He remains an adjunct Professor of Ophthalmology at Johns Hopkins. He has authored the first book on computers in medicine in 1984 and has published more than 200 scientific works in the New England Journal of Medicine, the Journal of the American Medical Association, and numerous other peer-reviewed publications. His published work has been cited by more than 24,000 people and he is in the top 1% of the most widely quoted scientists. He is listed in Who’s Who in America and Who’s Who in the World."
I'll keep everyone posted if any interesting details.
All the best. Dave
AI
